Tags Archive Navigation
icon
-
Media ReleaseNovartis: solide croissance du chiffre d’affaires et du bénéfice. La forte performance des marques existantes soutient la confiance dans les prévisions de croissance à moyen terme
-
Media ReleaseNovartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook
-
Media ReleaseNovartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity
-
Media ReleaseNovartis gibt neue Organisationsstruktur bekannt für schnelleres Wachstum, eine stärkere Pipeline und höhere Produktivität
-
Media ReleaseNovartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer
-
Media ReleaseNovartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021
-
Media ReleaseNovartis: a enregistré, en 2021, une croissance du chiffre d’affaires net à un chiffre dans le milieu de la fourchette, une expansion de la marge et une avancée du robuste pipeline
-
Media ReleaseNovartis erzielt 2021 ein Umsatzwachstum im mittleren einstelligen Bereich, verbessert die Margen und treibt die solide Pipeline voran
-
Media ReleaseFDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year
-
Media ReleaseNovartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)
-
Media ReleaseNovartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline
-
Media ReleaseNovartis to sell its Roche stake in a bilateral transaction to Roche
Pagination
- ‹ Previous page
- 1
- …
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- …
- 16
- › Next page